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(Nrf2)Atmospheric pressure gas plasma (AGP) generates reactive oxygen species (ROS) that induce apoptosis in
cultured cancer cells. The majority of cancer cells develop a ROS-scavenging anti-oxidant system regulated
by Nrf2, which confers resistance to ROS-mediated cancer cell death. Generation of ROS is involved in the
AGP-induced cancer cell death of several colorectal cancer cells (Caco2, HCT116 and SW480) by activation of
ASK1-mediated apoptosis signaling pathway without affecting control cells (human colonic sub-epithelial
myoﬁbroblasts; CO18, human fetal lung ﬁbroblast; MRC5 and fetal human colon; FHC). However, the
identity of an oxidase participating in AGP-induced cancer cell death is unknown. Here, we report that AGP
up-regulates the expression of Nox2 (NADPH oxidase) to produce ROS. RNA interference designed to target
Nox2 effectively inhibits the AGP-induced ROS production and cancer cell death. In some cases both colorectal
cancer HT29 and control cells showed resistance to AGP treatment. Compared to AGP-sensitive Caco2 cells,
HT29 cells show a higher basal level of the anti-oxidant system transcriptional regulator Nrf2 and its target
protein sulﬁredoxin (Srx) which are involved in cellular redox homeostasis. Silencing of both Nrf2 and Srx
sensitized HT29 cells, leads to ROS overproduction and decreased cell viability. This indicates that in HT29
cells, Nrf2/Srx axis is a protective factor against AGP-induced oxidative stress. The inhibition of Nrf2/Srx signaling
should be considered as a central target in drug-resistant colorectal cancer treatments.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer related
death in most of the developed countries [1]. Despite continuous im-
provement to the understanding of the molecular basis of colorectal
cancer and the associated progress in therapy, overall survival rates
have not increased. Most of the existing anti-cancer therapies, including
radio- or chemotherapy, damage DNA by generating reactive oxygen
species (ROS) and these have been found to be even less effective in
colorectal cancer treatment due to unknown intrinsic resistance.
Atmospheric pressure gas plasma (AGP) treatments have been very
effective in vitro against several cancer cell lines, including lung,
melanoma, colorectal, breast and hepatocellular carcinoma [2–7]. The
mechanism underlying its anticancer activity is still poorly understoodW 2070, Australia, Tel.: +61 2
hotmail.com (M. Ishaq),[2,3]. It is generally believed that AGP generated ROS induces oxidative
stress andDNA damage that leads to cancer cell apoptosis [6]. Apoptosis
may be activated by death receptor pathways (extrinsic) or through
mitochondrial pathway (intrinsic) via activation of cysteine proteases
called caspases, leading to caspase cascade activation and apoptosis
[8].We have recently reported that AGP induces apoptosis inmelanoma
cells by activating the TNF and ASK1 pathways [9]. AGP induces
apoptosis in a variety of cancer cells by producing ROS yet the source
of intracellular ROS generation is poorly understood.
Apoptosis signal regulating kinase-1 (ASK1) is amember of theMAP
kinase kinase kinase (MAP3K) family that activates the p38 and the JNK
kinases in response to various stimuli such as ROS, TNF and oxidative
stress [10–12]. In the inactive form, ASK1 remains associated with its
endogenous inhibitor, thioredoxin. Upon oxidative stress, the oxidized
form of thioredoxin is separated from ASK1, resulting in the activation
of the kinase. Activated ASK1 leads to the activation of downstream
kinases JNK and p38 MAPK which induce apoptosis [13].
Oxidative stress leads to apoptosis through a number of DNA-
damaging agents. Nox2 (gp91phox), a member of NADPH oxidases, me-
diates several cellular process including cell signaling, cell proliferation
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maintenance of redox homeostasis produced by these enzymes in
several tumors is currently under intensive investigation [16]. Nox2-
generated ROS can trigger intracellular signaling pathways involved in
redox homeostasis [17]. Cellular stresses may activate Nox-mediated
redox signaling in cells whichmay then respond to these adverse affects
either by activating stress kinases or by removing the seriously
damaged cells via induction of apoptosis. ASK1 is a well studied stress
kinase that is activated by ROS (such as H2O2) produced from NADPH
oxidases which subsequently activate p38 MAPK signaling pathways
[18]. These outcomes show that ASK1 is an important effector of Nox
enzymes in the redox signaling involved in cellular stress responses.
Transcriptional factor nuclear factor-erythroid 2-related factor 2
(Nrf2) induces several cytoprotective enzymes in response to oxidative
stress by binding via a cis-acting element termed ARE [19]. The abun-
dance of Nrf2 is constitutively low as a result of its targeted degradation
by Kelch-like ECH-associated protein 1 (Keap1). Nrf2 degradation is
slowed and protein accumulates in the nucleus under conditions of
oxidative stress, where it activates ARE-containing genes, with a net
antioxidative effect [19]. Oxidative stress-induced ROS generation or
knockdown of Keap1 in A549 human lung adenocarcinoma activates
the Keap1-Nrf2-ARE signaling pathway and up-regulates antioxidative
proteins such as sulﬁredoxin (Srx). The cytoprotective role of Srx
against oxidative stress-induced cell death has been observed in several
types of human cancer cells including those of skin and lung but not in
adjacent normal tissues [20–22]. In human lung cancer cell lines,
depletion of endogenous Srx suppresses cell migration and invasion in
culture and also inhibits tumor growth [20]. Peroxiredoxins (Prx) are
a group of protective enzymes that are able to reduce hydrogen perox-
ide and organic peroxides. Peroxiredoxins become hyperoxidised under
highly oxidizing conditions. Srx was found to reduce the hyperoxidised
peroxiredoxins, thus saving Prx from destruction [23]. Srx is an ATP-
dependent enzyme, which is up-regulated by transcriptional factor
Nrf2 and contributes to the protection of cells against oxidative stress
[24].
Despite several promising recent results on AGP-induced apoptosis
in a variety of human tumor cell lines, little is known about intracellular
mechanism involved in its anti-tumor activity. AGP is a source of ROS
which activates intracellular signaling pathways inducing oxidative
stress that ultimately leads to apoptosis. In contrast, cellular antioxidant
systems respond to AGP-generated ROS by activating several anti-
oxidative enzymes which protect cells. However speciﬁc cellular mech-
anisms involving AGP-induced oxidative stress or anti-oxidative re-
sponses are poorly understood. The aim of this study is to explore the
underlying cellular mechanism of AGP induced cancer cell death and
the apparent resistance observed in colorectal cancer cell lines.2. Materials and methods
2.1. Atmospheric pressure gas plasma treatment
The atmospheric pressure gas plasmas (AGP) jet device was
developed and custom-designed in our group as previously detailed
[9]. It is equipped with two electrodes: a metal wire inside the tube
and a metal ring outside the tube. A visible plasma discharge of the
length N 2.5 cm was produced upon helium gas ﬂow with the ﬂow
rate of 2 L/min through the quartz tube by applying AC high voltage of
1.1–1.8 kV and operating frequency of 230–270 kHz. Ambient air is
used to generate the reactive species. The plasma plume generated is
discontinuous and is referred to as ‘cold plasma’ due to the measured
low gas temperature (~35–40 °C) at the distal end of the plume. More
detail of the type of the plasma discharges and their applications
can be found elsewhere [25]. The AGP plume was applied directly
to the surface of the culture medium covering cells for deﬁned time
points.2.2. Cell culture and reagents
The human colorectal cancer cell lines Caco2, HCT116, SW480,
and HT29 were kindly provided by Dr Peter Molloy (Food & Nutrition
Flagship, CSIRO) and were maintained in McCoy's media (Invitrogen
from Life Technologies) plus 10% FBS. Human colonic sub-epithelial
myoﬁbroblasts; CO18 and human fetal lung ﬁbroblast; MRC5 cells
were purchased from ATCC and grown in MEM media plus 10% FBS.
Fetal human colon; FHC cells were purchased from ATCC (CRL-1831)
and grown in ATCC-formulated DMEM, supplemented with 10 mM
HEPES, 10 ng/ml cholera toxin, 0.005 mg/ml transferrin, 100 ng/ml hy-
drocortisone and 10% FBS. Caspase inhibitor Z-VAD-FMK (Cat#G7231),
N-acetylcystein amide (NAC) (Cat#A0737) were purchased from
Sigma-Aldrich. Human Srx cDNA clone plasmid (Cat#RG207654) and
control vector pCMV6-AC-GFP (Cat# PS100010) were purchased from
OriGene Technologies.
2.3. Cell viability and caspase 3/7 activity assay
Cells were treated with AGP for predetermined time periods as
indicated. Cell viability was quantiﬁed using Cell Titer 96 Aqueous
Non-radioactive Cell Proliferation (MTS) Assay (Cat#G5421 Promega)
and caspase 3/7 activitywasmeasured by using Caspase Glo 3/7 reagent
(Cat#G8091, Promega) following the manufacturer's protocol as
described previously [9]. In some experiments, the caspase inhibitor
zVAD-FMK (50 μM) or NAC (3 mM) were added 1–2 h prior to AGP
treatment.
2.4. Intracellular ROS measurement
Intracellular levels of ROS (H2O2; hydrogen peroxide, OH; hydroxyl
radicals and O2−superoxide) were measured using 5-(and-6)-
chloromethyl-2′-7′-dichlorodihydroﬂuorescein diacetate, acetyl ester
(CM-H2DCFDA) (Cat#C6827, Invitrogen,) following the manufacturer's
instructions as described previously [9]. Cells were stained with 10 μM
of CM-H2DCFDA for 30 min at 37 °C 1–2 h after AGP treatment. For
quantiﬁcation of intracellular ROS level, ﬂuorescence was measured at
490 nm (excitation) and at 530 nm (emission) using FLUOstar Omega
ﬂuorescence plate reader.
2.5. Gene expression analysis
For analysis of RNA or protein expression levels, cells were treated
with AGP for the indicated time points. In some experiments, NAC
(3 mM) were added 1–2 h prior to AGP treatment. Total RNA was
isolated using a TRIzol reagent (Cat#15596-026, Invitrogen) and
reverse transcribed using a Superscript cDNA synthesis kit (Bio-Rad)
as described previously [26]. Gene expression was assessed by
quantitative RT-PCR using SsoAdvanced SYBR Green Supermix
(Cat#172-5265, Bio-Rad) with Roche LightCycler 480 qPCR system.
The human oxidative stress PCR array primers library (Cat#HOSL-1,
RealTimePrimers.com, USA) was used to measure relative gene
expression of N90 genes involved in cellular oxidative stress response
pathways. For immunoblot analysis, protein was extracted using RIPA
lysis buffer (Cat#89901, Thermo Scientiﬁc) as described previously [9,
27]. Cytoplasmic and nuclear extracts from cells were prepared using
NE-PER nuclear and cytoplasmic extraction kit (Cat#78835, Thermo
Scientiﬁc) following the manufacturer's protocol. For Srx overexpres-
sion, Caco2 cells were transfected with Srx cDNA plasmid (pSrx)
and control vector pCMV6-AC-GFP (pControl) by lipofectamine
according to the manufacturer's instructions. Protein from each sample
was separated using SDS-PAGE (MP TGX 4–20%, cat#4561094, Bio-
Rad), and membranes were probed with indicated antibodies speciﬁc
for phospho-p38 MAPK (Thr180/Tyr182) (Cat#4511), p38 MAPK
(Cat#8690), Phospho-ASK1 (Thr845) (Cat#3765), ASK1 (Cat#8662)
and GAPDH from Cell Signaling Technology, Srx (Cat#sc-373829),
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393358), Keap1 (Cat#sc-15246), Nrf2 (Cat#sc-365949) and Nox2
(Cat#sc-130543) from Santa Cruz Biotechnology, goat anti-rabbit IgG
HRP (Cat#170-6515) and goat anti-mouse IgG HRP (Cat#170-6516)
from Bio-Rad. The proteins were visualized with a chemiluminescence
detection kit (Cat#170-5060, Bio-Rad).
2.6. RNA interference
Small interfering RNA (siRNA) speciﬁc for ASK1 (Cat#sc-29748), Srx
(Cat#sc-61622) and Nrf2 (Cat#sc-37030) were purchased from Santa
Cruz Biotechnology. Cells were transfectedwith siRNA by lipofectamine
(Invitrogen from Life Technologies) according to the manufacturer's in-
structions as described previously [9]. The silencing ability of all siRNAs
was determined by Western blot analysis. At 24 h post-transfection,
cells were treated with the AGP, after which cell viability, caspase 3/7
activity, ROS level, kinase activity and protein expression were studied.
2.7. Statistical analysis
All values were presented as mean ± standard deviation (SD)
of three independent experiments. Statistical differences between
control and treated groups were determined by one-way ANOVA orFig. 1. AGP generated ROS induced apoptosis in cancer cells. Colorectal cancer cells (Caco2, HCT116
human fetal lungﬁbroblast;MRC5and fetal humancolon; FHC)were treatedwith theAGP for 5,
was quantiﬁed using CM-H2DCFDA ﬂuorescence dye. Data are shown as fold change relative to
mined usingMTS/PMS assay over 24 h. (C) Caspases 3/7 activity measured by Caspase-Glo 3/7
enger NAC and then treatedwith AGP for 5, 15 and 30 s. Cell viability wasmeasured by usingMT
are mean ± of four independent experiments performed in triplicate. *p ≤ .05; ANOVA.Student's t-test where applicable. Differences were considered statisti-
cally signiﬁcant for *p b 0.05.
3. Results
3.1. AGP induces apoptosis in colorectal cancer cells by activating
ASK1 pathways
Previous work has shown that AGP-induced intracellular ROS
production is involved in the initiation of apoptotic responses in cancer
cells [6]. Here we veriﬁed that AGP treatment induced intracellular ROS
production as detected in colorectal cancer (CRC) cells (such as Caco2,
HCT116 and SW480) using a ROS-sensitive probe, H2DCFDA, to detect
the generation of intracellular ROS (includingH2O2; hydrogen peroxide,
OH; hydroxyl radicals and O2−; superoxide). In contrast, HT29 CRC and
control cells (human colonic sub-epithelial myoﬁbroblasts; CO18,
human fetal lung ﬁbroblast; MRC5 and fetal human colon; FHC) did
not show any signiﬁcant increase in levels of ROS after AGP treatment
(Fig. 1A). Recently, our group and other researchers have shown that
AGP can selectively kill various cancer cells in culture by inducing
apoptosis [2,4,6,9]. Based on this, we have determined the effect of
AGP on the proliferation of colorectal cancer cells and activity of
caspases 3/7 which are indicative of AGP-induced apoptosis. As shown
in the Fig. 1B, Caco2, SW480, HCT116 cells were very sensitive to AGP-, SW480 andHT29) and control cells (human colonic sub-epithelialmyoﬁbroblasts; CO18,
15 or 30 s or treatedonlywithHelium(He) gasﬂowas a control. (A) Intracellular ROS level
the control cells. Data is normalized against FHC control cells. (B) Cell viability was deter-
assay. (D) Caco2 cells were pre-treated for 1–2 h with caspase inhibitor zVAD or ROS scav-
S/PMS assay. Control cells were treated onlywithHe gas ﬂow in all experiments. All values
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treatment) while HT29 and normal control cells (CO18, MRC5 and FHC)
were resistant. Caspases 3/7 are members of the cysteine aspartic acid-
speciﬁc proteases (caspases) and play key effector roles in the induction
of apoptosis in cancer cells following the oxidative stress and DNA
damage. To further assess the apoptosis-inducing factors, we used
Caspase-Glo 3/7 luminescent assay to quantify the caspase-3 and -7
activities. As shown in Fig. 1C, the activity of apoptosis-inducing caspases
3/7 was increased in Caco2, HCT116 and SW480 CRC cells after the AGP
treatment with no signiﬁcant effects observed in the HT29 and normal
control cells. A dedicated cell proliferation test conducted under condi-
tions of reduced oxidative stress revealed that the AGP-induced cell
death was blocked by both the caspase inhibitor zVAD and also by
the ROS scavenger NAC (Fig. 1D). This suggests that AGP-induced cell
death in cancer cells was caused by generation of ROS and activation of
caspases 3/7. To explore mechanisms of AGP-induced cancer cell death
and resistance, we expanded our study on AGP to include the most
sensitive colorectal cancer cells (Caco2) and also resistant cells (HT29).
It has been reported that ROS play a key role in the activation of the
stress responseMAPK signaling pathways [28]. ROS treatment activates
ASK1 through distinct mechanisms and relays those signals to stress-
activated MAP kinases such as JNK and p38 [10]. Activated ASK1 then
activates JNK and p38, and this induces apoptosis through caspase
activation [10]. In order to investigate the ROS-induced activation of
ASK1 and the p38 MAPK stress response pathways, we treated Caco2
cells with AGP and then detected the ASK1 activity within 30 min of
AGP treatment using an antibody that speciﬁcally recognized the phos-
phorylated ASK1. Furthermore, downstream of ASK1, p38 kinase was
also activated by AGP treatment as detected by quantifying phosphory-
lated p38 protein (Fig. 2A). To correlate the link between AGP-induced
ROS generation and the activation of ASK1 pathway, we antagonized
ROS production by treating the cells with an antioxidant and a ROS
scavenger (NAC). NAC markedly reduced the phosphorylation of both
ASK1 and p38 after AGP treatment (2A). The inhibitory effect of NAC
on ASK1/p38 provides evidence that ROS is required for the activation
of these signaling pathways. To determine the speciﬁc role of ASK1
in AGP-mediated ASK1/p38 pathways during cancer cell death, we de-
pleted the ASK1 mRNA by interfering with RNA using a siRNA speciﬁc
to ASK1 (Fig. 2B). As shown in Fig. 2C, D&E, ASK1 depletion reduced
the AGP-induced p38 activation as well as subsequent cell death and
activity of caspases 3/7. Together, this indicates that ASK1 mediates
AGP-induced p38 activation and death of some target cancer cells.
3.2. AGP induced Nox2 to produce ROS
As described previously, ROS scavenger inhibits the activity of
NADPH oxidase (Nox) by blocking the ROS generated by these enzymes.
More recently, UV radiation has been shown to increase the activity of
NADPH oxidase (Nox) by the activation of signaling pathway that
increases the production of ROS [29]. Our results have shown that AGP
enhanced the production of intracellular ROS in cancer cells. AGP-
induced cancer cell death is mediated by ROS activity, which can be
blocked by ROS scavenger NAC. These ﬁndings lead us to look for the in-
tracellular sources of ROS produced in cancer cells which are activated
following AGP treatment. It is well known that Nox plays an important
role in the generation of ROS in response to oxidative stress and in reg-
ulating signaling transduction as part of the response to antioxidants
[30].
To investigate whether NADPH oxidase (Nox) might be involved in
AGP-induced ROS generation in AGP-sensitive colorectal cells, we mea-
sured the expression level of Nox genes 1–5 in Caco2 and HT29 cells
24 h after AGP treatment (30 s) by real-time RT-qPCR. As shown in
Fig. 3A, in Caco2 colorectal cancer cells, the basal levels of Nox1 and
Nox2 mRNA were higher than the basal levels of Nox3, Nox4 and
Nox5 mRNA. However after AGP treatment, Nox2 was highly up-
regulated compared to the very minimal effect on Nox1, Nox3, Nox4and Nox5 (Fig. 3A). Similarly in HT29 cells, the basal levels of Nox1
and Nox2 mRNA were higher than the basal levels of Nox3, Nox4 and
Nox5 mRNA (Sup. Fig. 2). However Nox2 gene expression was not
signiﬁcantly affected in HT29 cells after AGP treatment compared to
Caco2 cells (Sup. Fig. 2). We also detected that Nox2 expression
increased in Caco2 cells in a dose-dependent manner with respect to
AGP treatment (5, 15 and 30 s) (Fig. 3B). Next, we examined AGP-
induced up-regulation of cellular Nox2 gene expression at the protein
level by Western blot analysis which showed a dose-dependent (5, 15,
and 30 s) up-regulation of Nox2 after the AGP treatment (Fig. 3C). To
further investigate the involvement of the Nox2 oxidase system as a
major source of ROS generation after the AGP exposure, we studied
the effects of the depletion of Nox2 by RNA silencing (siRNA). The
Nox2 gene was silenced using a Nox2 speciﬁc siRNA in Caco2 cells as
shown in Fig. 3D. Consistent with the mechanistic involvement of oxi-
dative stress in Caco2 cells after the AGP treatment, a dose-dependent
increase in intracellular ROS production was observed which was
inversed in Nox2-silenced or NAC pre-treated Caco2 cells (Fig. 3E). In
addition, Nox2-silenced or NAC pre-treated Caco2 cells were resistant
to AGP-induced cell death compared to negative control siRNA treated
cells as measured using cell viability assays (Fig. 3F). These ﬁndings
provide evidence that Nox2 is involved in AGP-induced ROS production
and cancer cell death in vitro.
Taken together, these results conﬁrm that AGP treatment induces
speciﬁc redox alterations by up-regulating intracellular NADP oxidases
and ROS production in cultured cells.
3.3. AGP activated oxidative stress response signaling in colorectal cancer
cells
As shown above in Fig. 1, HT29 colorectal cancer cells showed resis-
tance to AGP-induced cell death compared to highly sensitive CRC;
Caco2, HCT116, and SW480 cells. Previous studies have shown that an
increase in ROS-scavenging and ROS-detoxifying enzymes protects can-
cer cells, with blocking of these defense systems conferring sensitivity
to radiation or chemotherapeutic drugs [31].
We examined the induction of cellular oxidative stress and themod-
ulation of the oxidative stress-response gene expression in HT29 colo-
rectal cancer cells treated with AGP for 30 s. A real-time PCR human
oxidative stress primers library was used to quantify the expression of
N90 genes involved in oxidative stress and modulation of stress re-
sponse. Expression of AGP-induced differential genes was monitored
in HT29 CRC cells and data showed several genes were involved in the
anti-oxidative cellular response (Supp Fig. 1). Sulﬁredoxin (Srx) was
one of the highly up-regulated genes in our qPCR library screen
and this was independently veriﬁed by RT-qPCR in a dose-dependent
manner (Fig. 4A). Next, AGP-induced up-regulation of cellular Srx
gene expressionwas examined at protein level byWestern blot analysis
which showed a dose-dependent up-regulation of gene expression after
theAGP treatment of 5, 15, and 30 s (Fig. 4B). Furthermore,we observed
that the AGP-induced Srx expression was signiﬁcantly higher in AGP-
resistant HT29 cells compared to AGP-sensitive Caco2 cancer cells. The
basal level of Srx in Caco2 cells was also less than in HT29 cells. In addi-
tion, AGP-induced Srx expression was reduced by the co-treatment
with ROS scavenger NAC. This indicates that AGP-induced ROS is con-
tributing to the up-regulation of Srx (Fig. 4C). To further investigate
the involvement of the Srx as an anti-oxidative protective system
against the AGP treatment, we studied the effects of the depletion of
Srx by RNA silencing (siRNA). Srx gene was silenced using Srx-speciﬁc
siRNA in HT29 cells as shown in Fig. 4D. Srx-silenced HT29 cells were
sensitive to AGP-induced cell death compared to the negative control
siRNA-treated cells as measured with cell viability assays (Fig. 4F). In
contrast, Srx-silenced Caco2 cells were sensitive to AGP-induced cell
death in an outcome that was similar to the negative control siRNA
treated cells (Fig. 4F). However, overexpression of Srx protein, achieved
by transfecting Srx cDNA plasmid in Caco2 cells (Fig. 4E), developed
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mid cells (Fig. 4G). These ﬁndings provide evidence that Srx is involved
in the resistance of HT29 colorectal cells to AGP-induced cell death.3.4. Nrf2 is involved in the protective response of HT29 cancer cells
Acknowledging that an impaired Keap1–Nrf2 system is found in
several cancer cell lines which showed resistance to oxidative stress,
we hypothesized that the resistance of HT29 CRC cells to AGP-inducedFig. 2. AGP activated ASK1-mediated signaling pathway causing cancer cell death. Caco2 colorectal
ed with AGP for the time periods indicated. (A) Western blot measurement of the ASK1 and p
phospho-speciﬁc antibody for ASK1; p-p38: phospho-speciﬁc antibody for p38). GAPDH antib
p38 protein. The band intensities were normalized against that of GAPDH. Data are expressed
Caco2 cells were transfected with ASK1 siRNA or control siRNA. GAPDH antibody was used as a
malized against that of GAPDH. Data are expressed as themean± SD, n= 3. *p≤ .05. (C)Weste
or control siRNA. 24 h post-transfection, cells were exposed to AGP for 30 s. GAPDH antibodyw
intensities were normalized against that of GAPDH. Data are expressed as themean± SD, n=3
pre-treatedwithNAC for 1–2 h and then treatedwith AGP as indicated time points 5, 15 and 30 s
determined by Caspase-Glo 3/7 assay. Control cells were treated onlywith He gas ﬂow in all exp
*p ≤ .05; ANOVA.death may arise because of the active anti-oxidant system mediated
by mutation of Keap1 or increased activity of Nrf2.
To explore this, we investigated the endogenous basal level expres-
sion of Nrf2 and Keap1 proteins in AGP-resistant and AGP-sensitive CRC
cells.WeperformedWestern blot analysis to examine the level of Keap1
and Nrf2 proteins in HT29 and Caco2 cells. Our results showed that Nrf2
protein was highly abundant in the nuclear fraction of HT29 cells, as
compared to its level in Caco2, where as Nrf2 expression in cytoplasmic
fraction were found to be similar in these two cell lines (Fig. 5A).
Additionally, the Keap1 protein level was reduced in HT29 cells,cancer cells were pre-treatedwith orwithout ROS scavenger NAC for 1–2 h and then treat-
38 kinase activity made using different antibodies as indicated in the ﬁgure (p-ASK1: S38
ody was used as a loading control. The relative bar graphs for p-ASK1, ASK1, p-p38 and
as the mean ± SD, n = 3. *p ≤ .05. (B) Western blot analysis of ASK1 protein expression.
loading control. The relative bar graphs for ASK1 protein. The band intensities were nor-
rn blot analysis of the p38 phospho activity. Caco2 cells were transfectedwith ASK1 siRNA
as used as loading control. The relative bar graphs for phos-p38 and p38 protein. The band
. *p≤ .05. (D&E) Caco2 cells were transfectedwith ASK1 siRNA or control siRNA for 24 h or
. Cell viabilitywasmeasured using aMTS/PMS assay over 24h and caspase 3/7 activitywas
eriments. All values aremean±of three independent experiments performed in triplicate.
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sion of the Nrf2-downstream target proteins NQO1 and AKR1C1 was
higher in HT29 cells compared with Caco2 cells (Fig. 5B)
Next we determined whether knockdown of Nrf2 could inhibit
AGP-induced antioxidant genes regulated by Nrf2. We used RNA
interference to inhibit Nrf2 expression in HT29 cells (Fig. 5C). We
found that AGP treatment of HT29 cells further induced the expression
of Nrf2 downstream genes such as Srx, NQO1 and AK1RC1, which were
inhibited by Nrf2 knockdown using RNAi (Fig. 5D). Analysis of cell via-
bility showed a signiﬁcant increase in AGP-induced cell death in Nrf2-
silenced HT29 cells in comparison to the negative control siRNA-
treated HT29 cells (Fig. 5E). In contrast, Nrf2 silenced Caco2 cells were
sensitive to AGP-induced cell death like the negative control siRNA-
treated cells (Sup. Fig. 3). In a similar way, Nrf2 silencing in HT29 cells
dramatically enhanced the activity of caspases 3/7 that induced apopto-
sis following AGP exposure compared to the negative control siRNA
treated HT29 cells (Fig. 5F). Evaluation of ROS levels indicated that si-
lencing of Nrf2 in HT29 led to a signiﬁcant increase in ROS productionFig. 3.AGP-inducedROS production is regulated byNox oxidases. (A) Caco2 cellswere treatedwith
level of Nox1, Nox2, Nox3, Nox4, and Nox5mRNA transcripts to control GAPDHwere determine
(p b 0.05). (B&C) Caco2 cells were treatedwith AGP for 5, 15 and 30 s. Nox2 gene expressionwa
siRNA or Control siRNA. Western blot used to measure Nox2 protein expression after 36–48
normalized against that of GAPDH. Data are expressed as the mean ± SD, n = 3. *p ≤ .05. (E
1–2 h and then treated with AGP for 5, 15 and 30 s. Cell viability measured by MTS/PMS assay
treated only with He gas ﬂow in all experiments. All values are mean ± of three independentafter AGP treatment in comparison to the control siRNA-treated HT29
cells which showed a very low level of ROS (Fig. 5G). Together, these
data showed that Nrf2 is involved in the regulation of the anti-oxidant
system that results in AGP-induced oxidative stress.
4. Discussion
In this study we have identiﬁed cellular factors involved in AGP-
induced death and resistance of colorectal cancer cells under culture
conditions.
Our results show that the AGP treatment induces intracellular ROS
production in a dose-dependent manner in most of the CRC cells tested
in this study. Previous work has shown that AGP induces the generation
of intracellular ROS in cancer cells [6,32,33] yet the exact mechanisms
are still unknown. To probe the mechanism of ROS production induced
by the AGP, we analyzed the response of NADPH oxidases enzymes to
AGP treatment which led to the enhanced intracellular ROS generation.
The level of expression of Nox2 in Caco2 cells was signiﬁcantlyAGP for the indicated time points. Cellswere then subjected to RNAextraction. The relative
d by qPCR. *, signiﬁcantly different from the corresponding value of control untreated cells
smeasured by RT-qPCR andWestern blotting. (D) Caco2 cells were transfectedwith Nox2
h of transfection. The relative bar graphs for Nox2 protein. The band intensities were
&F) Caco2 cells were transfected with Nox2 siRNA for 24 h or pre-treated with NAC for
and Caspase 3/7 activity measured by Caspase–Glo caspase 3/7 assay. Control cells were
experiments performed in triplicate. *p ≤ .05; ANOVA.
Fig. 4. Antioxidant Srx is involved in AGP-resistance in HT29 colorectal cancer cells. (A&B) HT29 cancer cells were treated with AGP for the indicated time points. Srx gene expression was
measured by RT-qPCR and Western blotting. (C) Western blot analysis of Srx protein expression in treated and un-treated control cells. HT29 and Caco2 cells were pre-treated with
NAC for 1–2 h and then treated with AGP for 30 s. GAPDH antibody was used as loading control. The relative bar graphs for Srx protein. The band intensities were normalized against
that of GAPDH. Data are expressed as the mean ± SD, n = 3. *p ≤ .05 (D) HT29 cells were transfected with Srx siRNA or control siRNA for 24 h. Srx protein expression was measured
by using speciﬁc antibody to Srx protein. GAPDH antibody was used as loading control. The relative bar graphs for Srx protein. The band intensities were normalized against that of
GAPDH. Data are expressed as the mean ± SD, n = 3. *p ≤ .05. (E) Caco2 cells were transfected with Srx cDNA plasmid (pSrx) or a control vector plasmid (pControl) for 24–36 h. Srx
protein expression was measured by using speciﬁc antibody to Srx protein. GAPDH antibody was used as a loading control. The relative bar graphs for Srx protein. The band intensities
were normalized against that of GAPDH. Data are expressed as themean± SD, n= 3. *p≤ .05. (F) HT29 and Caco2 cells were transfectedwith siControl or siSrx siRNAs for 24 h, followed
with AGP treatment for the indicated time points. Cell viabilitywasmeasured usingMTS/PMS assay 24h after treatment. (G) Caco2 cells were transfectedwith Srx cDNA plasmid (pSrx) or
control vector plasmid (pControl) for 24 h, followedwith AGP treatment for indicated time points. Cell viabilitywasmeasured usingMTS/PMS assay 24h after AGP treatment. Control cells
were treated only with He gas ﬂow in all experiments. All values are mean ± of three independent experiments performed in triplicate. *p≤ .05; ANOVA.
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both the AGP-induced ROS production and the associated cell death.
This demonstrates the role of Nox2 in the AGP-induced ROS generation
(Figs. 1 & 3).
It has previously been suggested that AGP-induced apoptosis report-
ed in a variety of cancer cell lines is caused by activating caspases 3/7 [4,
6,32,34] yet the mechanism remains unclear. Our recently published
results showed the involvement of TNF–ASK1 apoptosis pathways in
the AGP-induced death of cultured melanoma cells [9]. This current
study demonstrates the mechanism of the AGP-induced death in cul-
tured colorectal cancer cells.We found that the AGP selectively reduced
the proliferation of CRC cells by activating ASK1-p38 kinases andcaspases 3/7 inducing apoptosis without affecting normal control cells.
AGP-induced cell death was inhibited in Caco2 cells by pre-treatment
with caspase inhibitor zVAD or ROS scavenger NAC which also silenced
RNAi of ASK1 indicating that the AGP-induced cell death is probably
mediated by activating the ROS, ASK1 and caspases 3/7 apoptosis
pathways (Figs. 1&2).
We also found that the colorectal cancer cell line HT29was resistant
to the AGP-induced cell death. Similarly, the AGP-treatment did not
activate caspases 3/7 in HT29 cells, although there was a slight increase
in the production of ROS in HT29 cells compared to AGP-sensitive Caco2
cells (Fig. 1). To further elucidate themechanismof HT29 CRC resistance
to the AGP treatment, we propose that HT29 cells activate an
Fig. 5. Cellular Nrf2 antioxidant system contributes to HT29 cells resistance against AGP-induced cell death. (A) Western blot analysis of Nrf2 in Caco2 and HT29 colorectal cancer cells from
cytosolic and nuclear extract using speciﬁc antibody to Nrf2. Histone H1 and GAPDHwere used as a loading control for cytosolic and nuclear fractions respectively. The relative bar graphs
for Nrf2 andHistoneH1protein expression. The band intensitieswerenormalized against that ofGAPDH. Data are expressed as themean±SD, n=3. *p≤ .05. (B)Western blot analysis of
Keap1, NQO1 and AKR1C1 from whole cell lysate of Caco2 and HT29 colorectal cancer cells. GAPDH was used as a loading control. The relative bar graphs for Keap1, NQO1 and AKR1C1
protein expression. The band intensities were normalized against that of GAPDH. Data are expressed as themean± SD, n= 3. *p≤ .05. (C) HT29 cells were transfectedwith Nrf2 siRNA or
control siRNA for 24 h. Western blot analysis was used to quantify Nrf2 protein expression. GAPDH was used as a loading control. The relative bar graphs for Nrf2 protein. The band
intensities were normalized against that of GAPDH. Data are expressed as the mean ± SD, n = 3. *p ≤ .05. (D) HT29 cells were transfected with Nrf2 siRNA or control siRNA. 24 h
after transfection, cells were treatedwith AGP for 30 s.Western blot analysiswas used tomeasure the expression of Nrf2 target genes Srx, NQO1 and AKR1C1. GAPDHwas used as loading
control. The relative bar graphs for Srx, NQO1 and AKR1C1 protein expression. The band intensities were normalized against that of GAPDH. Data are expressed as themean± SD, n= 3.
*p≤ .05. (E, F&G) HT29 cells were treatedwith Nrf2 siRNA or control siRNA for 24 h. Cell viability was determined byMTS/PMS assay. Caspases 3/7 activity was quantiﬁed by Caspase-Glo
3/7 assay. Intracellular ROS productionwasmeasured by CM-H2DCFDAﬂuorescent dye. Control cells were treatedwith only He gas ﬂow in all experiments. All values aremean±of three
independent experiments performed in triplicate. *p≤ .05; ANOVA.
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AGP exposure. It is known that ROS-induced oxidative stress affects the
function of multiple redox-sensitive transcription factors and leads to
the up-regulation of anti-oxidant genes [35]. In our gene expression
study of the oxidative stress response in HT29 CRC cells (where N90
genes involved in oxidative stress response were quantiﬁed by RT-
qPCR after the AGP treatment), we found that the Srx gene expressionincreased signiﬁcantly after the AGP-treatment (Supp Fig. 1). We
also observed an elevated basal level of Srx protein expression in
unstimulated HT29 cells compared to AGP-sensitive Caco2 cells.
Furthermore, AGP-treatment signiﬁcantly up-regulated the level of
Srx protein expression in HT29 cells compared to Caco2 cells. In turn,
the ROS scavenger NAC blocked AGP-induced up-regulation of Srx. Ad-
ditionally, RNAi silencing of Srx in HT29 cells increased their sensitivity
Fig. 6. Proposed mechanisms of AGP-induced cell-death and cell-resistance against AGP treat-
ment in colorectal cancer cells. AGP as a source of extracellular ROS can activate cellular
NADPH oxidases (Nox) to generate intracellular ROS. High level of ROS can activate
ASK1-p38 mediated caspases 3/7 apoptotic pathways to induce apoptosis of cancer cells
(such as Caco2 colorectal cancer cells) which possess an inactive antioxidant system. In
contrast, some other types of cancer cells (such as HT29 colorectal cancer cells) possess
an active form of antioxidant regulator transcriptional factor Nrf2 and can respond rapidly
to any oxidative stress by inducing antioxidant enzymes (such as Srx) which can protect
cancer cells from the toxic effects of anti-cancer therapies.
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is highly expressed in human colon carcinomas and advanced
adenocarcinomas at clinical stages II–III which is associatedwith tumor-
igenicity and metastasis. However, Srx is not expressed in normal
human colon epithelial tissues and normal tissues [36]. The increased
Srx level was shown to enhance the proliferation rate of the cancer
cells [20,37]. Srx expression has been found to be regulated by Nrf2 in
cancer cells in response to stimuli of oxidative stress [38–40]. Our data
strongly suggest that Srx protein is involved in the protection of HT29
CRC cells against AGP-induced cell death.
Nrf2 regulates the cellular cytoprotective defense against oxidative
stress by transactivation of detoxiﬁcation enzymes and antioxidant
proteins such as NAD(P)H quinine oxidoreductase-1 (NQO-1) and
glutathione S-transferases (GST), hemeoxyginase-1 (HO-1) [41].
Under physiological conditions, Keap 1 is a negative regulator of Nrf2
and maintains its low basal level by constantly targeting Nrf2 for
ubiquitin-mediated protein degradation [42]. Keap1–Nrf2 signaling
pathway is defective in several human cancers such as lung cancer
[43], gall bladder cancer [44], breast cancer [45], prostate cancer [46]
and malignant glioma [47]. The impaired Keap1 activity activates
Nrf2 to develop a protective mechanism against the surrounding
microenvironment, eventually resulting in cancer cell proliferation
and resistance to anti-cancer therapeutics. Our study showed that
Nrf2 target genes such as Srx, NQO1 and AKR1C1 were up-regulated
after the AGP treatment. Keap1 protein, which is an inhibitor of Nrf2,
was highly up-regulated in Caco2 cells compared to HT29 cells. Nrf2
silencing inhibited the AGP-induced Nrf2 target genes Srx, NQO1 and
AKR1C1, showing that regulation of these antioxidant proteins may
depend on Nrf2 activity (Fig. 5). We also observed that Nrf2 silencing
in HT29 cells signiﬁcantly altered the intracellular redox state by up-
regulating the ROS production that can highly sensitize cultured HT29
cells to AGP induced cell death (Fig. 5).
While the work we present here has focussed on the Nox2–ASK1
pathways, we acknowledge that there are several other genes and
cellular pathways involved in ROS production, apoptosis and the anti-
oxidant response. Indeed, other researchers have shown that PI3/AKT
[48], LTB4/BLT2 [49], INK4a/ARF [50], p21/WAF1 [51,52] and GSTP1/
CBR1 [53] signaling pathways are involved in ROS production and the
anti-oxidant response.
5. Summary
Here in this study we have used colorectal cancer cells to elucidate
the role of AGP-induced cancer cell death in vitro. We have shown
how ROS are produced and how they induce cell death by AGP treat-
ment. In cultured colorectal cancer cells, a signiﬁcant increase of ROS
is detected after AGP treatment. These increases were attenuated by
the treatment with the ROS scavenger anti-oxidant NAC. Nox2 was
found to be the primary source of ROS after AGP treatment as indicated
by the decreased ROS production and apoptotic indices following Nox2
gene silencing. We also have found that AGP activated ASK1 in colorec-
tal cancer cells induced apoptosis which was inhibited by silencing the
ASK1 or using ROS scavenger NAC or by silencing of Nox2. This impli-
cates NADPH Nox2 activation in the production of ROS and shows that
activation of apoptosis signaling is required for the death of cancer
cells. Moreover, we provide evidence for a signiﬁcant role of AGP-
induced Nox2 in ROS production and ASK1 activation in the induction
of apoptosis.
We have also shown that the Nrf2–Srx mediated anti-oxidant sys-
tem is an important determinant of AGP resistance in colorectal cancer
cells.We observed that AGP induces Srx antioxidant protein expression,
which is the reason for the resistance of HT29 cancer cells to AGP-
induced apoptosis. Knockdown of Nrf2 or Srx by small interfering RNA
(siRNA) increased the sensitivity of HT29 cancer cells to AGP-induced
cell death. In addition we found that HT29 cancer cells expressed a con-
stitutively higher level of Nrf2 in the nucleus and a very low level ofKeap1 which may be the reason for the protective responses of HT29
cells against the AGP-induced death. Together, data provides evidence
that the Nox2-induced ROS initiates ASK1-mediated apoptosis in AGP-
treated colorectal cancer cells in culture while the Nrf2–Srx regulated
anti-oxidant system protected cancer cells from the AGP-induced
death (Fig. 6).
These results open new avenues for the selective control of the spec-
iﬁed targets responsible for the regulation of oxidative stress and anti-
oxidative responses in cancer cells in vitro. This information may also
be relevant to other types of cancer cells and our data is promising in
considering the future development of next-generation anti-cancer
therapies including those based on atmospheric pressure gas plasmas.
6. Conclusion
In conclusion, this study has shown for the ﬁrst time that the AGP in-
duced NADPH oxidases generate intracellular ROS which play a role in-
ducing the death of cultured colorectal cancer cells by activating the
ASK1-mediated apoptosis pathways. Furthermore, we have shown that
AGP-resistant cancer cells develop an efﬁcient antioxidant systemmedi-
ated by Nrf2–Srx signaling to protect the cells from the toxic effects of
this anti-cancer therapy. Finally, this study reveals the set of viable clin-
ical targets that could be used to effectively control the levels of oxidative
stress and anti-oxidative defense in colorectal cancer cells in the devel-
opment of next-generation clinical treatment of drug-resistant tumors.
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